A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities.
D000477:Alkylating Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D000818:Animals; D006168:Guinea Pigs; D066298:In Vitro Techniques; D009019:Morphinans / Q000138:chemical synthesis* / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D009271:Naltrexone / Q000031:analogs & derivatives*; D009292:Narcotic Antagonists / Q000138:chemical synthesis*; D009294:Narcotics / Q000138:chemical synthesis*; D010111:Oxymorphone / Q000031:analogs & derivatives*; D011957:Receptors, Opioid / Q000187:drug effects*
D000477:Alkylating Agents; D009019:Morphinans; D009292:Narcotic Antagonists; D009294:Narcotics; D011957:Receptors, Opioid; D009271:Naltrexone; C024524:beta-funaltrexamine; C024525:oxymorphone fumarate methyl ester; D010111:Oxymorphone